Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06518213
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-07-12
Brief Title:
Efficacy and Safety of First-line ART With BICFTCTAF Introduced at the First Clinical Visit
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy and Safety of First-line Antiretroviral Therapy ART With BictegravirEmtricitabineTenofovir Alafenamide BICFTCTAF Introduced at the First Clinical Visit a Real-life Retrospective Single Arm Single Center Study
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Bictegraviremtricitabinetenofovir alafenamide BICFTCTAF is a recommended first-line antiretroviral regimen Croatia has a centralized care for people living with HIV PLWH and all persons are seen and treated in a single center preferably in a same-day initiation model whenever suitable This retrospective cohort study evaluated antiretroviral therapy ART naïve PLWH who initiated BICFTCTAF in a same-day model The goal of the study is to assess safety and efficacy of this model by collecting information from the electronic database of the Croatian HIV Reference Centre
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None